CONMED的空头股数在7月份下降了11.6%，该公司第二季度每股收益为0.98美元，超出预期0.06美元。 CONMED's short interest dropped 11.6% in July, and the company reported $0.98 EPS in Q2, exceeding estimates by $0.06.
医疗科技公司CONMED的空头股价在7月下降了11.6%,从405万股下降到358万股, 股价保值率为8.0天. Medical tech company CONMED's short interest dropped 11.6% in July, falling from 4.05M shares to 3.58M shares, with an 8.0 days-to-cover ratio. 来自Piper Sandler、Stifel Nicolaus、摩根大通（JPMorgan Chase & Co）、Needham & Company LLC和富国银行（Wells Fargo & Company）等领先公司的分析师对其评级为持有、增持或买入，平均评级为“适度买入”，平均目标价为79.80美元。 Analysts from leading firms including Piper Sandler, Stifel Nicolaus, JPMorgan Chase & Co, Needham & Company LLC, and Wells Fargo & Company have rated it with a hold, overweight, or buy, resulting in an average "Moderate Buy" rating and an average price target of $79.80. 公司在第二季度的每股收益 (EPS) 报告为0.98美元,超过分析师的共识估计0.06美元,并宣布每季度每股股息为0.20美元,应于10月4日支付. The company reported $0.98 earnings per share (EPS) in Q2, exceeding analysts' consensus estimates by $0.06 and announcing a quarterly dividend of $0.20 per share, payable on October 4th.